*001119987
*00520250613121232.0
*007ta
*008110930s2005    no            000 u eng d
*00901004cam a2200229 c 4500
*019  $bl
*035  $a(EXLNZ-47BIBSYS_NETWORK)990606349794702201
*035  $a(NO-LaBS)13893912(bibid)
*035  $a(NO-TrBIB)060634979
*035  $a060634979-47bibsys_network
*040  $aNO-TrBIB$bnob$ekatreg
*1001 $aBjorvatn, Afsaneh$0(NO-TrBIB)90805189$_29683500
*24510$aFondaparinux sodium compared with enoxaparin sodium :$ba cost-effectiveness analysis$cAfsane Bjorvatn and Frode Kristiansen
*260  $aBergen$bDepartment of Economics, University of Bergen$c[2005]
*300  $aS. [121]-130$bfig.
*4901 $aReprint series / Department of Economics, University of Bergen$vno. 315
*500  $aSærtrykk av: American journal of cardiovascular drugs, 5(2), 2005
*588  $aKatalogisert etter omslag
*7001 $aKristiansen, Frode$d1959$0(NO-TrBIB)10000249$_20592700
*830 0$aReprint series (Universitetet i Bergen. Institutt for økonomi) (trykt utg.)$x0809-1676$vno. 315$w999002769164702201$_14068000
*901  $a80
*999  $aoai:nb.bibsys.no:990606349794702202$b2021-11-14T19:49:58Z$z990606349794702202
^